COVID-19 & seizure/epilepsy

PASIRI SITHINAMSUWAN

PHRAMONGKUTKLAO HOSPITAL
Background: COVID-19

Novel coronavirus

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

WHO

- Pandemic
Background: COVID-19

Can infect at all age ranges and genders

Typical symptoms

◦ Respiratory symptoms

Atypical symptoms

◦ GI symptoms, anosmia, confusion
◦ Mimic: Dengue hemorrhagic fever, unexplained cardiac arrest
◦ Kawasaki disease in children, toxic shock syndrome → multisystem inflammatory syndrome in children

Mortality: varies
Previous coronaviruses & Neurology
Previous coronaviruses & Neurology

Severe acute respiratory syndrome (SARS) in 2003

Middle East respiratory syndrome coronavirus (MERS-CoV)

- ? neurotropic
- Inflammation and demyelination
- Encephalitis, encephalomyelitis
- Seizure 23% and 8.6% respectively
Novel coronavirus (COVID-19) & neurology
Novel coronavirus (COVID-19) & neurology

- Headache (13%)
- Dizziness (17%)
- Alteration of consciousness (8%)
- Stroke (3%)
- Incoordination (0.5%)
- Seizure (0.5%)
Novel coronavirus (COVID-19) & seizure/epilepsy
COVID-19 and acute symptomatic seizures
COVID-19 and acute symptomatic seizures

Incidence and risk for acute symptomatic seizures in OVID-19

Multicenter survey 42 hospital, 11 neurologists

Retrospective 304 patients, 108 severe COVID-19 condition

No epilepsy

Only 2 patients developed seizure-like symptoms from stress, hypocalcemia
COVID-19 and acute symptomatic seizures

Case report, Vollono C., Italy, in Seizure 2020

A primary presentation: a focal status epilepticus
COVIDs and seizures

Direct viral neuroinvasion (viral encephalitis)

Trigger immune system (autoimmune encephalitis)

Hypoxia, organ failure, metabolic derangements

Therapeutic intervention: drug
Limitations

Non-convulsive status epilepticus (NCSE)

Electroencephalogram, EEG

Salzburg Consensus Criteria for Non-Convulsive Status Epilepticus

Under-recognition
COVID-19 effects epilepsy
COVID-19 effects epilepsy

As precipitating factors: fever, stress, hypoxemia

Medication withdrawal

SARS outbreak/pandemic in 2003

- From Taiwan, 227 patients
- 22% medication inaccessible
- 12% uncontrolled seizures
- 2 case developed status epilepticus
COVID-19 effects epilepsy

Antiepileptic medications

- Anti-viral therapies
  - Drug-to-drug interaction with AEDs
  - Cardiac conduction abnormalities, prolonged QT-interval, PR interval, arrhythmia, and hypotension: avoid AEDs with same side effects

- In severe COVID-19 with organ failure: dosage adjustment
Epilepsy effects COVID-19
Epilepsy effects COVID-19

No strong evidence that epilepsy alone is susceptible host for COVID-19
Seizure treatment approach during COVID-19
Seizure treatment approach during COVID-19

Clinical, subclinical seizure, status epilepticus

- As general principal of seizure/epilepsy treatment
- Avoid side effect, drug interaction, dosage adjustment in organ failure
- Short-term AEDS during acute and transitional phase in first acute symptomatic seizure for increase seizure threshold
Proper management plan for epilepsy during COVID-19
Proper management plan for epilepsy during COVID-19

Telemedicine, video consultations

Medicine delivery
Conclusion
COVID-19

Low prevalence of acute asymptomatic seizures

Subclinical or non-convulsive): may be under-recognized

Follow general principal of seizure/epilepsy treatment
เอกสารอ้างอิง


เอกสารอ้างอิง


Thank you